Atypical hemolytic-uremic syndrome: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 17: | Line 17: | ||
[[Category:Hematology]] |
[[Category:Hematology]] |
||
[[Category:Nephrology]] |
[[Category:Nephrology]] |
||
[[Category:Thrombosis]] |
|||
Revision as of 11:32, 15 August 2020
Background
Pathophysiology
- Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity
Diagnosis
- Genetic mutation analysis of complement regulatory proteins (CFH, CFI, MCP, C3, CFB, THBD) and anti-CFH antibodies
Management
- Often unable to distinguish from TTP, so plasma exchange should be initiated promptly
- If no improvement on PLEX and there is significant renal involvement, consider an aHUS-specific treatment
- Eculizumab to inhibit complement, ideally with full meningococcal vaccination beforehand
